Please ensure Javascript is enabled for purposes of website accessibility

Rockville-based Novavax reports larger quarterly loss

Novavax Inc., of Rockville, a drug delivery company developing vaccines aimed at a broad range of infectious diseases worldwide, reported a net loss of $10 million, or 7 cents per diluted share, for the first quarter of 2013, compared to a net loss of $7.3 million, or 6 cents per share, for the year-ago period.

Revenue totaled $3.8 million versus $4.6 million in the comparable 2012 period.

The company attributed the increased loss and drop in revenue to a higher level of clinical trials targeting influenza in the 2012 period compared to no similar clinical trials in the 2013 quarter.

Analysts on average forecast a loss of 6 cents per share and revenue of $5.54 million.